A detailed history of Federated Hermes, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 675,347 shares of SAGE stock, worth $3.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
675,347
Previous 670,468 0.73%
Holding current value
$3.87 Million
Previous $7.28 Million 33.13%
% of portfolio
0.01%
Previous 0.02%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$7.02 - $13.08 $34,250 - $63,817
4,879 Added 0.73%
675,347 $4.87 Million
Q2 2024

Aug 08, 2024

BUY
$10.58 - $17.9 $7.09 Million - $12 Million
670,468 New
670,468 $7.28 Million
Q4 2023

Jan 31, 2024

SELL
$17.1 - $22.26 $2.83 Million - $3.68 Million
-165,451 Reduced 99.68%
534 $11,000
Q3 2023

Nov 13, 2023

BUY
$16.75 - $48.98 $2.78 Million - $8.13 Million
165,985 New
165,985 $3.42 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $489,305 - $675,462
-17,780 Reduced 70.1%
7,584 $245,000
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $434,700 - $647,025
-14,155 Reduced 35.82%
25,364 $840,000
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $202,829 - $257,833
5,473 Added 16.08%
39,519 $1.68 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $247,236 - $352,309
6,141 Added 22.01%
34,046 $1.51 Million
Q2 2021

Aug 16, 2021

BUY
$54.88 - $79.29 $204,921 - $296,068
3,734 Added 15.45%
27,905 $1.59 Million
Q1 2021

May 13, 2021

SELL
$70.65 - $96.76 $9.66 Million - $13.2 Million
-136,696 Reduced 84.97%
24,171 $1.81 Million
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $3.51 Million - $5.36 Million
-60,175 Reduced 27.22%
160,867 $13.9 Million
Q3 2020

Nov 12, 2020

BUY
$41.13 - $62.45 $143,420 - $217,763
3,487 Added 1.6%
221,042 $13.5 Million
Q2 2020

Aug 13, 2020

BUY
$25.95 - $43.15 $3.67 Million - $6.1 Million
141,313 Added 185.35%
217,555 $9.05 Million
Q1 2020

May 13, 2020

BUY
$26.15 - $77.24 $1.99 Million - $5.89 Million
76,242 New
76,242 $2.19 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $677,600 - $917,506
-4,830 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $762,415 - $884,324
4,830 New
4,830 $884,000
Q3 2018

Nov 13, 2018

SELL
$138.11 - $169.04 $745,655 - $912,646
-5,399 Closed
0 $0
Q2 2018

Aug 10, 2018

SELL
$140.36 - $175.76 $3.97 Million - $4.97 Million
-28,271 Reduced 83.96%
5,399 $845,000
Q1 2018

May 09, 2018

BUY
$152.15 - $192.33 $3.55 Million - $4.48 Million
23,316 Added 225.19%
33,670 $5.42 Million
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $45.1 Million - $124 Million
-742,203 Reduced 98.62%
10,354 $0
Q3 2017

Nov 13, 2017

BUY
$61.4 - $88.52 $46.2 Million - $66.6 Million
752,557
752,557 $46.9 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.